NeOnc Showcases Two Brain Cancer Drug Programs at SNO as FDA Meetings Approach

NeOnc (NASDAQ: NTHI) to present findings from 2 investigational brain cancer programs at the 31st Annual Meeting of the Society for Neuro-Oncology (SNO)

Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.